Zhongsheng Pharmaceutical announced that Onradivir tablets, a class of innovative drugs independently developed by its holding subsidiary, were approved for marketing in May 2025; recently, a phase III clinical trial of the drug with the new indication “treatment of influenza A with a high risk of complications” was approved by the State Drug Administration to enroll young people and adults aged 12 and above with influenza A participants.

Zhongsheng Pharmaceutical announced that Onradivir tablets, a class of innovative drugs independently developed by its holding subsidiary, were approved for marketing in May 2025; recently, a phase III clinical trial of the drug with the new indication “treatment of influenza A with a high risk of complications” was approved by the State Drug Administration to enroll young people and adults aged 12 and above with influenza A participants.